<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have evaluated the neuroprotective effects of the decahydroisoquinoline LY377770, a novel iGlu5 kainate receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, in two models of <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>, induced in gerbils by bilateral carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> (BCAO) for 5 min, produced a large increase in locomotor activity at 96 hr post-occlusion and a severe loss of CA1 cells in the hippocampus histologically at 120 hr post-occlusion </plain></SENT>
<SENT sid="2" pm="."><plain>LY377770 (80 mg/kg i.p </plain></SENT>
<SENT sid="3" pm="."><plain>30 min before or 30 min after BCAO followed by 40 mg/kg i.p. administered at 3 and 6 hr after the initial dose) attenuated the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-induced <z:hpo ids='HP_0000752'>hyperactivity</z:hpo> and provided (92%) and (29%) protection in the CA1 cells respectively </plain></SENT>
<SENT sid="4" pm="."><plain>This protection was greater than that seen with maximally tolerated doses of other <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> (CGS19755, CPP, MK-801, ifenprodil, eliprodil, HA-966, ACEA1021, L701,324, NBQX, LY293558, GYKI52466 and LY300164) </plain></SENT>
<SENT sid="5" pm="."><plain>Focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> was induced by infusing 200 pmol of endothelin-1 (Et-1) adjacent to the middle cerebral artery and LY377770 was administered at 80 mg/kg i.p. immediately, 1 or 2 hr post-occlusion followed by 40 mg/kg i.p </plain></SENT>
<SENT sid="6" pm="."><plain>3 and 6 hr after the first dose </plain></SENT>
<SENT sid="7" pm="."><plain>The <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, measured 72 hr later, was reduced by LY377770 when given immediately (P&lt;0.01), at 1 hr (P&lt;0.05) but not significantly at 2 hr post-occlusion </plain></SENT>
<SENT sid="8" pm="."><plain>Reference compounds, LY293558 (20 mg/kg i.p. and then 10 mg/kg as above) and MK-801 (2.5 mg/kg i.p </plain></SENT>
<SENT sid="9" pm="."><plain>), both administered immediately post-occlusion produced significant (P&lt;0.05) but somewhat less neuroprotection </plain></SENT>
<SENT sid="10" pm="."><plain>In parallel microdialysis studies, LY377770 (75 mg/kg i.p.) attenuated <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-induced increases in extracellular levels of <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi>, but not of <z:chebi fb="40" ids="18243">dopamine</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain>In conclusion, these results indicated that iGlu5 kainate receptors play a central role in ischaemic brain damage following global and focal <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>LY377770 is a novel, soluble, systemically active iGlu5 <z:chebi fb="68" ids="48706">antagonist</z:chebi> with efficacy in global and focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>, even when administered post-occlusion </plain></SENT>
<SENT sid="13" pm="."><plain>LY377770 may therefore be useful as a neuroprotectant in man </plain></SENT>
</text></document>